Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Market Cap	10.56B
Revenue (ttm)	37.46M
Net Income (ttm)	-88.37M
Shares Out	122.62M
EPS (ttm)	-0.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150,208
Average Volume	243,049
Open	86.70
Previous Close	86.40
Day's Range	85.80 - 87.40
52-Week Range	73.00 - 122.00
Beta	-0.01
RSI	50.72
Earnings Date	Mar 17, 2026

About Gongwin Biopharm Holdings

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6617

Financial Performance

In 2024, Gongwin Biopharm Holdings's revenue was 32.04 million, an increase of 69.39% compared to the previous year's 18.92 million. Losses were -82.55 million, -10.31% less than in 2023.